Antithrombotic Treatment in Antiphospholipid Syndrome: A Review

Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by circulating autoantibodies that recognize cell surface phospholipids and phospholipid-binding proteins. APS is an autoimmune disorder associated with recurrent thrombosis of arterial or venous vessels and/or recurrent obs...

Full description

Saved in:
Bibliographic Details
Published in:Immuno 2024-12, Vol.4 (4), p.620-628
Main Authors: Siniscalchi, Carmine, Bernardi, Francesca Futura, Di Micco, Pierpaolo, Perrella, Alessandro, Meschi, Tiziana, Trama, Ugo
Format: Article
Language:English
Subjects:
Antibodies
Anticoagulants
antiphospholipid syndrome
Aspirin
Autoimmune diseases
catastrophic antiphospholipid syndrome
Clinical medicine
direct anticoagulant
Drug dosages
heparins
Lupus
Miscarriage
Obstetrics
Pregnancy
Prevention
Thromboembolism
Thrombosis
warfarin
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by circulating autoantibodies that recognize cell surface phospholipids and phospholipid-binding proteins. APS is an autoimmune disorder associated with recurrent thrombosis of arterial or venous vessels and/or recurrent obstetric complications as miscarriages. APS can be divided into primary or secondary clinical syndrome because of the possible association with other autoimmune systemic diseases as systemic lupus erythematosus (SLE). Vitamin K antagonists remain the mainstay of treatment for most patients with APS and, based on current data, appear superior to the more targeted direct oral anticoagulants. However, the choice of the type of antithrombotic drug is based on the anamnesis of affected patients: patients with previous arterial or venous thrombosis may benefit from anticoagulants, while patients with previous obstetric diseases may benefit from aspirin, but several clinical exceptions may be evaluated. This short review is dedicated to underlining the main clinical evidence for patients affected by APS or CAPS (catastrophic antiphospholipid syndrome) in order to prevent recurrent thrombosis.
ISSN:2673-5601
2673-5601
DOI:10.3390/immuno4040036